Common Contracts
2 similar Investor Rights Agreement contracts by Kolltan Pharmaceuticals Inc
KOLLTAN PHARMACEUTICALS, INC. AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • September 12th, 2014 • Kolltan Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT, dated as of March 13, 2014 (this “Agreement”), by and among Kolltan Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and holders of the Company’s Series A Convertible Preferred Stock, $.001 par value (the “Series A Preferred Stock”), party hereto (the “Series A Holders”), Series B Convertible Preferred Stock, $.001 par value (the “Series B Preferred Stock”), party hereto (the “Series B Holders”), Series C Convertible Preferred Stock, $.001 par value (the “Series C Preferred Stock”), party hereto (the “Series C Holders”) and Series D Convertible Preferred Stock, $.001 par value (the “Series D Preferred Stock”), party hereto, listed on Exhibit A (together with certain other persons who become such as provided herein, the “Holders”), amends and restates the Amended and Restated Investor Rights Agreement, dated as of March 1, 2012, by and among the Company and the Holders, as previously amended and/or restated (the “Prior A
KOLLTAN PHARMACEUTICALS, INC. AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • August 8th, 2014 • Kolltan Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT, dated as of March 13, 2014 (this “Agreement”), by and among Kolltan Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and holders of the Company’s Series A Convertible Preferred Stock, $.001 par value (the “Series A Preferred Stock”), party hereto (the “Series A Holders”), Series B Convertible Preferred Stock, $.001 par value (the “Series B Preferred Stock”), party hereto (the “Series B Holders”), Series C Convertible Preferred Stock, $.001 par value (the “Series C Preferred Stock”), party hereto (the “Series C Holders”) and Series D Convertible Preferred Stock, $.001 par value (the “Series D Preferred Stock”), party hereto, listed on Exhibit A (together with certain other persons who become such as provided herein, the “Holders”), amends and restates the Amended and Restated Investor Rights Agreement, dated as of March 1, 2012, by and among the Company and the Holders, as previously amended and/or restated (the “Prior A
